TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CLAREMONT, Calif., Nov. 22, 2016 -- Kiwa Bio-Tech Products Group Corporation (OTCQB:KWBT). On November 21, 2016, Kiwa Bio-Tech Products Group Corporation ("Kiwa" or the “Company”) reported its operating results for its third quarter ended September 2016. For the third quarter, Kiwa reported revenue of $1,261,544 and net income of $93,601. For the nine months ended September 30, 2016, Kiwa reported revenue of $1,971,639 and net income of $331,707.
Kiwa also reported that its wholly-owned subsidiary, Kiwa Bio-Tech (Beijing) Co., LTD, has been granted the required sales permit for fertilizers issued by the Chinese government. As a result, it projects US$8,000,000 in 4th quarter sales of fertilizers in China.
Mr. Xiaoqiang Yu, sales director of the Company, said that ‘‘once Kiwa (Beijing) obtained the required Chinese fertilizer sales license, Kiwa (Beijing) can expect sales of nearly 40,000 tons of fertilizer products in the fourth quarter, which includes sales to both existing and new customers”. Mr. Yu also said that the peak season for sales of fertilizer in China is generally the fourth quarter. “Now that we have the fertilizer sales permit, we are now able to transition our sales from our prior sales agent to Kiwa (Beijing)."
For more information on Kiwa and its products, please refer to the Company’s website at www.kiwabiotech.com or the Company filings with the United States Securities and Exchange Commission, available for free at www.sec.gov.
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the U.S. Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
CONTACT: Kiwa Bio-Tech Products Group Corporation Yvonne Wang [email protected]
